Loading...
Market
Will Brenus Pharma complete Phase I clinical trials for its cancer vaccine by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcement from Brenus Pharma or clinical trial registries
Story
Brenus Pharma Secures €22.2M ($25M) to Accelerate Cancer Vaccine Trials
Sep 18, 2024, 07:37 AM
Brenus Pharma, a Lyon-based biotech company specializing in the development of precision cancer vaccines, has successfully raised €22.2 million ($25 million) in a Series A funding round. The financing was led by Angelor and will be used to accelerate clinical trials of its cancer vaccines. This significant investment underscores the growing interest and support for innovative cancer treatment solutions in the biotech sector.
View original story
Similar markets
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%
Yes • 50%
No • 50%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%